Search

Your search keyword '"Naito, Tateaki"' showing total 185 results
Start Over Author "Naito, Tateaki" Publication Year Range Last 3 years
185 results on '"Naito, Tateaki"'

1. The efficacy and safety of anamorelin among patients with diabetes

Author

Ando, Kenju, Naito, Tateaki, Hamauchi, Satoshi, Miura, Keita, Nishibori, Yuichiro, Tonsho, Ayumi, Matsuda, Suguru, Morita, Meiko, Sekikawa, Motoki, Doshita, Kosei, Kodama, Hiroaki, Yabe, Michitoshi, Morikawa, Noboru, Iida, Yuko, Mamesaya, Nobuaki, Kobayashi, Haruki, Ryo, Ko, Wakuda, Kazushige, Ono, Akira, Kenmotsu, Hirotsugu, Murakami, Haruyasu, Yamazaki, Kentaro, and Takahashi, Toshiaki

Published
2024
Full Text
View/download PDF

3. Concordance of ALK fusion gene-rearrangement between immunohistochemistry and next-generation sequencing

Author

Wakuda, Kazushige, Morita, Meiko, Sekikawa, Motoki, Morikawa, Noboru, Miura, Keita, Doshita, Kosei, Iida, Yuko, Kodama, Hiroaki, Mamesaya, Nobuaki, Kobayashi, Haruki, Ko, Ryo, Ono, Akira, Kenmotsu, Hirotsugu, Naito, Tateaki, Murakami, Haruyasu, Muramatsu, Koji, Kawata, Takuya, Mori, Keita, Shimizu, Tetsuo, Gon, Yasuhiro, and Takahashi, Toshiaki

Published
2024
Full Text
View/download PDF

4. Effect of polypharmacy on the outcomes of older patients with advanced non-small-cell lung cancer treated with PD-1/PD-L1 inhibitors: A retrospective cohort study

Author

Morikawa, Noboru, Naito, Tateaki, Morita, Meiko, Sekikawa, Motoki, Doshita, Kosei, Yabe, Michitoshi, Kodama, Hiroaki, Miura, Keita, Iida, Yuko, Mamesaya, Nobuaki, Kobayashi, Haruki, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Kenmotsu, Hirotsugu, Murakami, Haruyasu, and Takahashi, Toshiaki

Published
2024
Full Text
View/download PDF

11. Correction to: First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1

Author

Nishio, Makoto, Ohe, Yuichiro, Ikeda, Satoshi, Yokoyama, Toshihide, Hayashi, Hidetoshi, Fukuhara, Tatsuro, Sato, Yuki, Tanaka, Hiroshi, Hotta, Katsuyuki, Sugawara, Shunichi, Daga, Haruko, Okamoto, Isamu, Kasahara, Kazuo, Naito, Tateaki, Li, Li, Gupta, Ravi G., Bushong, Judith, and Mizutani, Hideaki

Published
2023
Full Text
View/download PDF

15. Long-term survival data of patients with limited disease small cell lung cancer: a retrospective analysis

Author

Doshita, Kosei, Kenmotsu, Hirotsugu, Omori, Shota, Tabuchi, Yuya, Kawabata, Takanori, Kodama, Hiroaki, Nishioka, Naoya, Miyawaki, Eriko, Iida, Yuko, Miyawaki, Taichi, Mamesaya, Nobuaki, Kobayashi, Haruki, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Naito, Tateaki, Murakami, Haruyasu, Mori, Keita, Harada, Hideyuki, Kaneko, Takeshi, and Takahashi, Toshiaki

Published
2022
Full Text
View/download PDF

20. Exploring the relationship between anorexia and therapeutic efficacy in advanced lung cancer treatment: a retrospective study.

Author

Doshita, Kosei, Naito, Tateaki, Matsuda, Suguru, Morita, Meiko, Sekikawa, Motoki, Miura, Keita, Kodama, Hiroaki, Yabe, Michitoshi, Morikawa, Noboru, Iida, Yuko, Mamesaya, Nobuaki, Kobayashi, Haruki, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Murakami, Haruyasu, Kenmotsu, Hirotsugu, and Takahashi, Toshiaki

Subjects
*THERAPEUTIC use of antineoplastic agents, *ANOREXIA nervosa treatment, *CANCER relapse, *ANTINEOPLASTIC agents, *TREATMENT effectiveness, *RETROSPECTIVE studies, *CANCER patients, *LUNGS, *DESCRIPTIVE statistics, *IMMUNE checkpoint inhibitors, *CANCER chemotherapy, *LUNG tumors, *ANOREXIA nervosa, *MEDICAL records, *ACQUISITION of data, *LUNG cancer, *PROGRESSION-free survival, *COMPARATIVE studies, *OVERALL survival, *PLATINUM, *DISEASE complications
Abstract

Background: Chemotherapy‐induced anorexia is a common occurrence in patients undergoing treatment for advanced lung cancer. However, the relationship between chemotherapy‐induced anorexia and weight loss during platinum‐based chemotherapy combined with immune checkpoint inhibitors is unclear. This study explored the relationship between chemotherapy‐induced anorexia and therapeutic outcomes in patients with stage IV non‐small‐cell lung cancer undergoing platinum‐based chemotherapy combined with immune checkpoint inhibitors. Methods: The study retrospectively reviewed the medical records of 106 patients with stage IV non‐small‐cell lung cancer treated with platinum‐based chemotherapy and immune checkpoint inhibitors between January 2019 and October 2022. The incidence of weight loss and its association with treatment efficacy was assessed in the chemotherapy‐induced anorexia group. Chemotherapy‐induced anorexia, nausea, and vomiting were evaluated using Common Terminology Criteria for Adverse Events v 5.0. Progression‐free and overall survival were used to measure treatment efficacy. Results: Chemotherapy‐induced anorexia was observed in 13.2% of patients. These patients exhibited significant weight loss at 6 and 9 weeks after treatment initiation compared to those in the non‐chemotherapy‐induced anorexia group. Progression‐free and overall survival were shorter in the chemotherapy‐induced anorexia group than in the non‐chemotherapy‐induced anorexia group, but the difference was not statistically significant. Conclusions: Chemotherapy‐induced anorexia was associated with significant weight loss and reduced treatment efficacy in patients with stage IV non‐small‐cell lung cancer. These results highlight the importance of implementing robust supportive care for chemotherapy‐induced anorexia to mitigate weight loss and uphold treatment effectiveness during platinum‐based chemotherapy combined with immune checkpoint inhibitors. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Prognostic Impact of Postoperative Recurrence in Patients With Epidermal Growth Factor Receptor–Positive Non‐Small Cell Lung Cancer.

Author

Morita, Meiko, Ono, Akira, Sekikawa, Motoki, Doshita, Kosei, Miura, Keita, Kodama, Hiroaki, Yabe, Michitoshi, Morikawa, Noboru, Iida, Yuko, Mamesaya, Nobuaki, Kobayashi, Haruki, Ko, Ryo, Wakuda, Kazushige, Kenmotsu, Hirotsugu, Naito, Tateaki, Murakami, Haruyasu, Isaka, Mitsuhiro, Ohde, Yasuhisa, and Takahashi, Toshiaki

Published
2024
Full Text
View/download PDF

23. Efficacy of second-line chemotherapy in patients with pulmonary large cell neuroendocrine carcinoma

Author

Iida, Yuko, primary, Wakuda, Kazushige, additional, Kenmotsu, Hirotsugu, additional, Doshita, Kosei, additional, Kodama, Hiroaki, additional, Nishioka, Naoya, additional, Miyawaki, Eriko, additional, Miyawaki, Taichi, additional, Mamesaya, Nobuaki, additional, Kobayashi, Haruki, additional, Omori, Shota, additional, Ko, Ryo, additional, Ono, Akira, additional, Naito, Tateaki, additional, Murakami, Haruyasu, additional, Sugino, Takashi, additional, Gon, Yasuhiro, additional, and Takahashi, Toshiaki, additional

Published
2024
Full Text
View/download PDF

24. Exploring the Relationship Between Anorexia and Therapeutic Efficacy in Advanced Lung Cancer Treatment: A Retrospective Study

Author

Doshita, Kosei, primary, Naito, Tateaki, additional, Matsuda, Suguru, additional, Morita, Meiko, additional, Sekikawa, Motoki, additional, Miura, Keita, additional, Kodama, Hiroaki, additional, Yabe, Michitoshi, additional, Morikawa, Noboru, additional, Iida, Yuko, additional, Mamesaya, Nobuaki, additional, Kobayashi, Haruki, additional, Ko, Ryo, additional, Wakuda, Kazushige, additional, Ono, Akira, additional, Murakami, Haruyasu, additional, Kenmotsu, Hirotsugu, additional, and Takahashi, Toshiaki, additional

Published
2024
Full Text
View/download PDF

25. Suitability of frozen cell pellets from cytology specimens for the Amoy 9‐in‐1 assay in patients with non‐small cell lung cancer.

Author

Kodama, Hiroaki, Murakami, Haruyasu, Mamesaya, Nobuaki, Kobayashi, Haruki, Omori, Shota, Wakuda, Kazushige, Ko, Ryo, Ono, Akira, Kenmotsu, Hirotsugu, Naito, Tateaki, Matsumoto, Shingo, Goto, Koichi, Shimizu, Tetsuo, Gon, Yasuhiro, and Takahashi, Toshiaki

Subjects
RNA analysis, DNA analysis, CYTOLOGY, CANCER treatment, POLYMERASE chain reaction, RETROSPECTIVE studies, DESCRIPTIVE statistics, FROZEN tissue sections, LUNG cancer, COLLECTION & preservation of biological specimens, SENSITIVITY & specificity (Statistics), SPECIALTY hospitals, SEQUENCE analysis, EPIDERMAL growth factor receptors
Abstract

Background: The AmoyDx Pan lung cancer PCR panel (AmoyDx PLC panel) has been approved as a companion diagnostic tool for multiple anticancer agents in patients with non‐small cell lung cancer (NSCLC). However, the suitability of cytology specimens as samples for the AmoyDx PLC panel remains unclear. We evaluated the performance of frozen cell pellets from cytology specimens (FCPs) in the Amoy 9‐in‐1 assay, a preapproval assay of the AmoyDx PLC panel. Methods: We retrospectively collected data of NSCLC patients enrolled in LC‐SCRUM‐Asia from the Shizuoka Cancer Center between September 2019 and May 2021. Results: A total of 49 cases submitted FCPs for evaluation of oncogenic driver alterations and were assessed using Amoy 9‐in‐1 and next‐generation sequencing (NGS) assays. The success rates of DNA and RNA analyses using the Amoy 9‐in‐1 were both 100%, compared with 86% and 45%, respectively, using NGS assays. Oncogenic driver alterations were detected in 27 (55%) and 23 (47%) patients using Amoy 9‐in‐1 and NGS, respectively. No inconsistent results were observed among 19 cases in which both assays showed successful detection. In the remaining 30 cases, 10 had inconsistent results: nine oncogenic driver alterations (3 MET, 2 ALK, 2 ROS1, and 2 KRAS) were detectable only in Amoy 9‐in‐1, and one epidermal growth factor receptor (EGFR) mutation was detectable only in NGS. Conclusion: FCPs can be successfully used in the AmoyDx PLC panel, with higher success rate compared with the NGS assay. The AmoyDx PLC panel may be an option in cases when insufficient tissue sample is available for the NGS assay. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

26. Relationship between patterns of immunohistochemical conventional neuroendocrine markers and efficacy of immune check point inhibitors in patients with extensive disease small cell lung cancer

Author

Iida, Yuko, primary, Wakuda, Kazushige, additional, Kawata, Takuya, additional, Morita, Meiko, additional, Sekikawa, Motoki, additional, Doshita, Kosei, additional, Yabe, Michitoshi, additional, Kodama, Hiroaki, additional, Miura, Keita, additional, Morikawa, Noboru, additional, Mamesaya, Nobuaki, additional, Kobayashi, Haruki, additional, Ko, Ryo, additional, Ono, Akira, additional, Kenmotsu, Hirotsugu, additional, Naito, Tateaki, additional, Murakami, Haruyasu, additional, Gon, Yasuhiro, additional, and Takahashi, Toshiaki, additional

Published
2024
Full Text
View/download PDF

28. The barriers to interprofessional care for cancer cachexia among Japanese healthcare providers: A nationwide survey

Author

Naito, Tateaki, primary, Wakabayashi, Hidetaka, additional, Aso, Sakiko, additional, Konishi, Masaaki, additional, Saitoh, Masakazu, additional, Baracos, Vickie E., additional, Coats, Andrew J., additional, Anker, Stefan D., additional, Sherman, Lawrence, additional, Klompenhouwer, Tatiana, additional, Shirotani, Noriyasu, additional, Inui, Akio, additional, and Arai, Hidenori, additional

Published
2023
Full Text
View/download PDF

29. Prognostic impact of postoperative recurrence in patients with epidermal growth factor receptor-positive non-small cell lung cancer.

Author

Morita, Meiko, primary, Ono, Akira, additional, Sekikawa, Motoki, additional, Doshita, Kosei, additional, Miura, Keita, additional, Kodama, Hiroaki, additional, Yabe, Michitoshi, additional, Morikawa, Noboru, additional, Iida, Yuko, additional, Mamesaya, Nobuaki, additional, Kobayashi, Haruki, additional, Ko, Ryo, additional, Wakuda, Kazushige, additional, Kenmotsu, Hirotsugu, additional, Naito, Tateaki, additional, Murakami, Haruyasu, additional, Isaka, Mitsuhiro, additional, Ohde, Yasuhisa, additional, and Takahashi, Toshiaki, additional

Published
2023
Full Text
View/download PDF

32. Association between oligo-residual disease and patterns of failure during EGFR-TKI treatment in EGFR-mutated non-small cell lung cancer: a retrospective study

Author

Miyawaki, Taichi, Kenmotsu, Hirotsugu, Kodama, Hiroaki, Nishioka, Naoya, Miyawaki, Eriko, Mamesaya, Nobuaki, Kobayashi, Haruki, Omori, Shota, Ko, Ryo, Wakuda, Kazushige, Ono, Akira, Naito, Tateaki, Murakami, Haruyasu, Mori, Keita, Harada, Hideyuki, Endo, Masahiro, Takahashi, Kazuhisa, and Takahashi, Toshiaki

Published
2021
Full Text
View/download PDF

35. Safety and efficacy of amrubicin with primary prophylactic pegfilgrastim as second‐line chemotherapy in patients with small cell lung cancer

Author

Sekikawa, Motoki, primary, Murakami, Haruyasu, additional, Morita, Meiko, additional, Doshita, Kosei, additional, Miura, Keita, additional, Kodama, Hiroaki, additional, Morikawa, Noboru, additional, Iida, Yuko, additional, Mamesaya, Nobuaki, additional, Kobayashi, Haruki, additional, Ko, Ryo, additional, Wakuda, Kazushige, additional, Ono, Akira, additional, Kenmotsu, Hirotsugu, additional, Naito, Tateaki, additional, Chiba, Hirofumi, additional, and Takahashi, Toshiaki, additional

Published
2023
Full Text
View/download PDF

36. Diagnosis and outcomes of cachexia in Asia: Working Consensus Report from the Asian Working Group for Cachexia

Author

Arai, Hidenori, primary, Maeda, Keisuke, additional, Wakabayashi, Hidetaka, additional, Naito, Tateaki, additional, Konishi, Masaaki, additional, Assantachai, Prasert, additional, Auyeung, Wai Tung, additional, Chalermsri, Chalobol, additional, Chen, Wei, additional, Chew, Justin, additional, Chou, Ming‐Yueh, additional, Hsu, Chih‐Cheng, additional, Hum, Allyn, additional, Hwang, In Gyu, additional, Kaido, Toshimi, additional, Kang, Lin, additional, Kamaruzzaman, Shahrul Bahyah, additional, Kim, Miji, additional, Lee, Jenny Shun Wah, additional, Lee, Wei‐Ju, additional, Liang, Chih‐Kuang, additional, Lim, Wee Shiong, additional, Lim, Jae‐Young, additional, Lim, Yen Peng, additional, Lo, Raymond See‐Kit, additional, Ong, Terence, additional, Pan, Wen‐Harn, additional, Peng, Li‐Ning, additional, Pramyothin, Pornpoj, additional, Razalli, Nurul Huda, additional, Saitoh, Masakazu, additional, Shahar, Suzana, additional, Shi, Han Ping, additional, Tung, Heng‐Hsin, additional, Uezono, Yasuhito, additional, von Haehling, Stephan, additional, Won, Chang Won, additional, Woo, Jean, additional, and Chen, Liang‐Kung, additional

Published
2023
Full Text
View/download PDF

37. Concordance of ALK fusion gene-rearrangement between immunohistochemistry and next-generation sequencing

Author

Wakuda, Kazushige, primary, Morita, Meiko, additional, Sekikawa, Motoki, additional, Morikawa, Noboru, additional, Miura, Keita, additional, Doshita, Kosei, additional, Iida, Yuko, additional, Kodama, Hiroaki, additional, Mamesaya, Nobuaki, additional, Kobayashi, Haruki, additional, Ko, Ryo, additional, Ono, Akira, additional, Kenmotsu, Hirotsugu, additional, Naito, Tateaki, additional, Murakami, Haruyasu, additional, Muramatsu, Koji, additional, Kawata, Takuya, additional, Shimizu, Tetsuo, additional, Gon, Yasuhiro, additional, and Takahashi, Toshiaki, additional

Published
2023
Full Text
View/download PDF

39. Incidence and Treatment Outcome of Radiation Pneumonitis in Patients With Limited-stage Small Cell Lung Cancer Treated With Concurrent Accelerated Hyperfractionated Radiation Therapy and Chemotherapy

Author

Doshita, Kosei, primary, Tabuchi, Yuya, additional, Kenmotsu, Hirotsugu, additional, Omori, Shota, additional, Kawabata, Takanori, additional, Kodama, Hiroaki, additional, Nishioka, Naoya, additional, Miyawaki, Eriko, additional, Iida, Yuko, additional, Mamesaya, Nobuaki, additional, Kobayashi, Haruki, additional, Ko, Ryo, additional, Wakuda, Kazushige, additional, Ono, Akira, additional, Naito, Tateaki, additional, Murakami, Haruyasu, additional, Mori, Keita, additional, Harada, Hideyuki, additional, Kaneko, Takeshi, additional, and Takahashi, Toshiaki, additional

Published
2023
Full Text
View/download PDF

40. Impact of Early Chemotherapy Resumption on the Outcome after Staphylococcus aureus Bacteremia in Patients with Solid Tumors: A Retrospective Study in a Single Tertiary Cancer Center in Japan.

Author

Edagawa, Shunji, Naito, Tateaki, Yamamoto, Shuhei, Terada, Norihiko, Nakaya, Yuichiro, Mori, Keita, and Kurai, Hanako

Subjects
*TUMOR treatment, *TUMOR diagnosis, *BACTEREMIA, *CANCER patient psychology, *BLOOD, *CAUSES of death, *SPECIALTY hospitals, *CELL culture, *CANCER chemotherapy, *TERTIARY care, *RETROSPECTIVE studies, *MANN Whitney U Test, *FISHER exact test, *TREATMENT effectiveness, *CANCER treatment, *INFECTION control, *TREATMENT failure, *STAPHYLOCOCCUS aureus, *MASS spectrometry, *DESCRIPTIVE statistics, *HYPOTHESIS, *RESEARCH funding, *ANTIBIOTICS, *CANCER patient medical care, *DISEASE complications
Abstract

Objective. Staphylococcus aureus bacteremia (SAB) in patients with solid tumors poses a dilemma between infection control and cancer treatment. We aimed to explore whether early resumption of chemotherapy yielded unfavorable outcomes in oncologic patients with SAB. Methods. We retrospectively reviewed patients who received chemotherapy within 90 days of SAB onset from 2011 to 2020. We divided patients who resumed chemotherapy into two groups by the median time from the negative blood culture to the chemotherapy resumption. We investigated the association with treatment failure, which included recurrence after completion of SAB treatment, relapse during antibiotics therapy, 90-day all-cause mortality after initiation of antibiotics, and 30-day all-cause mortality after the resumption of chemotherapy. Results. Among the 78 eligible patients, 36 patients resumed chemotherapy. The median interval to the chemotherapy resumption was 17.5 days. Two patients in the early resumption group and one in the late resumption group died within 90 days after initiating antibiotics. One patient in the early resumption group experienced SAB recurrence. None of the patients experienced SAB relapse or died within 30 days of resuming chemotherapy. Conclusion. Early resumption of chemotherapy may not be directly associated with unfavorable outcomes in oncological patients with SAB under appropriate infection management. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

41. Efficacy and safety of carboplatin and etoposide in older extensive‐stage small‐cell lung cancer patients with a poor performance status

Author

Mamesaya, Nobuaki, primary, Kodama, Hiroaki, additional, Iida, Yuko, additional, Kobayashi, Haruki, additional, Ko, Ryo, additional, Wakuda, Kazushige, additional, Ono, Akira, additional, Kenmotsu, Hirotsugu, additional, Naito, Tateaki, additional, Murakami, Haruyasu, additional, Shimizu, Tetsuo, additional, Gon, Yasuhiro, additional, and Takahashi, Toshiaki, additional

Published
2023
Full Text
View/download PDF

44. Clinical impact of tumour burden on the efficacy of PD ‐1/ PD‐L1 inhibitors plus chemotherapy in non‐small‐cell lung cancer

Author

Miyawaki, Taichi, primary, Kenmotsu, Hirotsugu, additional, Doshita, Kosei, additional, Kodama, Hiroaki, additional, Nishioka, Naoya, additional, Iida, Yuko, additional, Miyawaki, Eriko, additional, Mamesaya, Nobuaki, additional, Kobayashi, Haruki, additional, Omori, Shota, additional, Ko, Ryo, additional, Wakuda, Kazushige, additional, Ono, Akira, additional, Naito, Tateaki, additional, Murakami, Haruyasu, additional, Mori, Keita, additional, Harada, Hideyuki, additional, Endo, Masahiro, additional, Takahashi, Kazuhisa, additional, and Takahashi, Toshiaki, additional

Published
2022
Full Text
View/download PDF

46. MO44-5 The clinical outcome of patients with oligometastatic non-small cell lung cancer treated with first-line immunotherapy

Author

Miyawaki, Taichi, primary, Kenmotsu, Hirotsugu, additional, Doushita, Kousei, additional, Kodama, Hiroaki, additional, Nishioka, Naoya, additional, Miyawaki, Eriko, additional, Mamesaya, Nobuaki, additional, Kobayashi, Haruki, additional, Omori, Shota, additional, Ko, Ryo, additional, Wakuda, Kazushige, additional, Ono, Akira, additional, Naito, Tateaki, additional, Murakami, Haruyasu, additional, and Takahashi, Toshiaki, additional

Published
2022
Full Text
View/download PDF

48. Predicting the efficacy of first‐line immunotherapy by combining cancer cachexia and tumor burden in advanced non‐small cell lung cancer

Author

Miyawaki, Taichi, primary, Naito, Tateaki, additional, Doshita, Kosei, additional, Kodama, Hiroaki, additional, Mori, Mikiko, additional, Nishioka, Naoya, additional, Iida, Yuko, additional, Miyawaki, Eriko, additional, Mamesaya, Nobuaki, additional, Kobayashi, Haruki, additional, Omori, Shota, additional, Ko, Ryo, additional, Wakuda, Kazushige, additional, Ono, Akira, additional, Kenmotsu, Hirotsugu, additional, Murakami, Haruyasu, additional, Mori, Keita, additional, Harada, Hideyuki, additional, Endo, Masahiro, additional, Takahashi, Kazuhisa, additional, and Takahashi, Toshiaki, additional

Published
2022
Full Text
View/download PDF

49. Efficacy and safety of anamorelin in patients with cancer cachexia: Post‐hoc subgroup analyses of a placebo‐controlled study.

Author

Takayama, Koichi, Takiguchi, Toru, Komura, Naoyuki, and Naito, Tateaki

Subjects
CACHEXIA, CANCER patients, LEAN body mass, BODY mass index, PATIENT safety
Abstract

Background: Cachexia, a disorder associated with anorexia, inflammation, and muscle wasting, is frequent in cancer patients. We performed post‐hoc analyses of the ONO‐7643‐04 study to investigate the efficacy and safety of anamorelin in subgroups of Japanese patients with non‐small cell lung cancer (NSCLC). Methods: The patients were divided into subgroups by baseline characteristics, including sex, age, body mass index, prior weight loss, performance status (PS), concomitant anticancer therapy, and number of previous chemotherapy regimens. The changes from baseline through to 12 weeks for lean body mass (LBM), body weight, and appetite were calculated. Appetite was evaluated using the quality of life questionnaire for cancer patients treated with anticancer drugs (QOL‐ACD) item 8 score. Responder rates were defined as the maintenance/improvement of LBM (≥0 kg), body weight (≥0 kg), or QOL‐ACD item 8 score (≥0) from baseline to all evaluation time points. Safety was evaluated in patients subgrouped by age and PS. Results: Anamorelin resulted in greater improvements versus placebo in LBM, body weight, and appetite in most subgroups. Anamorelin was also associated with greater LBM, body weight, and appetite responder rates than placebo in nearly all subgroups. Among anamorelin‐treated patients, adverse drug reactions (ADRs) tended to be more frequent with increasing age (<65 years, 19.2%; ≥65 to <75 years, 45.9%; ≥75 years, 60.0%) and PS score (PS 0–1, 38.4%; PS 2, 60.0%). The frequency of serious ADRs was 2.7% and 0% in the PS 0–1 and PS 2 subgroups, respectively. Conclusion: This study of NSCLC patients with cancer cachexia revealed consistent improvements in LBM, body weight, and appetite across most subgroups of anamorelin‐treated patients. This study also demonstrated the tolerability of anamorelin regardless of age and PS, with a low incidence of serious ADRs in each subgroup. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results